AlphaYou
Overview
Smart money at a glance
Filings to Oct 1, 2026No insider open-market trades in 90 days (SEC Form 4). Congress: net selling of $15K to $50K in 180 days.
- Company insidersSEC Form 4, last 90 days
- $0No open-market trades
- CongressSTOCK Act, last 180 days
- -$15K to -$50K netNet selling
- Big fundsSEC 13F, quarter ended Jun 30, 2026
- 3 added, 4 cutMore cutting
- Federal contractsUSAspending.gov, last 12 months
- No awardsNone on record
Key stats
Fundamentals Sep 30- Open
- $144.81
- 52-wk high
- $165.43
- High
- $146.18
- 52-wk low
- $117.98
- Low
- $144.46
- Prev close
- $146.88
- Mkt cap
- $276.95B
- P/E
- 22.2x
- Volume
- 1.60M
- Fwd P/E
- 14.7x
- Beta
- 0.49
- Div yield
- 3.23%
- P/S
- 4.9x
- P/B
- 6.5x
- Profit margin
- +22.5%
- Op margin
- +34.6%
- ROE
- +30.3%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about NVS filings
Are insiders buying or selling Novartis AG ADR (NVS) stock?
Neither. Novartis AG ADR (NVS) insiders filed no open-market purchases or sales in the 90 days to Oct 1, 2026, according to SEC Form 4 filings.
Which members of Congress have traded NVS recently?
Rep. Kevin Hern (R) sold $15K to $50K on Aug 27, 2026, disclosed 29 days later. In total, 1 member disclosed 1 NVS trade with trade dates in the last 180 days, filed a median 29 days after trading.
How current is this NVS smart-money data?
This summary uses filings available on Oct 1, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position.
What funds are doing
Buys/Adds (3)
- MI
Millennium
$118.8M
bought
- FC
Farallon Capital
$56.9M
bought
- CI
Citadel
$50.3M
bought
What Congress is doing
Sells (1)
How top traders are positioned
No tracked top-trader positions in NVS right now.
Live Hyperliquid positioning - not every stock is covered
Activist stakes, short interest & more
Earnings
Earnings came in 9.5% above what analysts expected.
Earnings per share
$2.20 expected
Reports Oct 27, 2026, in 26 days
Estimates as of Sep 30, 2026
EPS expected
$2.20 to $2.26
Revenue expected
5 analysts
Last 30 days
Analysts raising estimates
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $14.36B | $13.33B | $13.52B | $14.42B |
| Cost of what it sold | $3.54B | $3.54B | $3.46B | $3.68B |
| Gross profit | $10.82B | $9.79B | $10.06B | $10.74B |
| What it spent | ||||
| Research and development | $2.94B | $2.84B | $2.74B | $2.76B |
| Sales and admin | $3.31B | $3.44B | $3.14B | $3.24B |
| Other operating costs | $66.0M | — | — | — |
| Total operating expenses | $6.32B | $6.27B | $5.83B | $6.00B |
| What was left | ||||
| Operating profit | $4.50B | $3.52B | $4.24B | $4.74B |
| Interest on debt | $281.0M | $304.0M | $343.0M | $462.3M |
| Profit before tax | $4.20B | $3.22B | $3.84B | $4.27B |
| Tax | $266.0M | $813.9M | $683.0M | $1.01B |
| Net profit | $3.93B | $2.41B | $3.16B | $3.27B |
| EBITDA | $5.84B | $5.07B | $5.41B | $5.94B |
Technicals
Price structure
This stock is under pressure, and looks overbought after a fast run-up.
Trend
Under pressure
20 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage is mixed
Diluted earnings per share (diluted EPS) of Novartis AG Sponsored ADR – HAN:NOTA
NeutralSep 30Novartis AG Lobbyists, 1998
NeutralSep 29Weekly Recap: Novartis $30B market loss and CEO sees midterm sales growth
Leans bearishSep 28Novartis AG Lobbyists, 2026
NeutralSep 27Bronstein, Gewirtz & Grossman, LLC Is Investigating Novartis AG (NVS) And Encourages Shareholders to Connect
BearishSep 25Failure of Novartis’ Pelacarsen Could Reshape the Lp(a) Race for CRISPR and Ionis
NeutralSep 24Novartis (NVS): Company Profile, Stock Price, News, Rankings
BullishSep 24Novartis licenses BoomRay radioligand asset for $900M
Leans bullishSep 22
Macro
33 macro signals shaping NVS right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results